New drug combo targets Hard-to-Treat cancers in early trial
Disease control
Recruiting now
This early-phase trial tests an experimental drug called ABX-001, given alone or with the immunotherapy pembrolizumab, in 27 people with advanced solid tumors who have no standard treatment options left. The main goal is to check safety and find the right dose, while also looking…
Phase: PHASE1 • Sponsor: Abalos Therapeutics GmbH • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC